MetaCap

Repligen Corporation Company Profile

NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

163.84-3.38 (-2.02%)

At close: Oct 8, 4:00 PM ET · Delayed 15 min

Repligen at a glance

Repligen Corporation (NASDAQ: RGEN) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Waltham, MA. Repligen is led by Mr. Olivier Loeillot and employs about 2,000 people. The company's shares have traded publicly since 1986.

At a market capitalization of $10.40 billion, it is considered a large-cap company. Its SEC Central Index Key (CIK) is 0000730272, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Repligen do?

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Repligen Corporation
Ticker
NASDAQ: RGEN
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Olivier Loeillot
Employees
2,000
Headquarters
Building 1, Waltham, MA, United States
Phone
781 250 0111
IPO year
1986
Market cap
$10.40B
SEC CIK
0000730272

Companies similar to Repligen

RGEN peer companies
CompanyPrice% ChgMarket capCompare
IBRXImmunityBio Inc.9.91+1.64%$10.50Bvs RGEN
TWSTTwist Bioscience Corporation152.05-2.31%$10.08Bvs RGEN
KRYSKrystal Biotech Inc.327.30+0.84%$9.69Bvs RGEN
PCVXVaxcyte Inc.65.02-2.90%$9.67Bvs RGEN
TECHBio-Techne Corp72.45-0.11%$11.36Bvs RGEN
QGENQiagen N.V.44.53-0.58%$9.20Bvs RGEN
KYMRKymera Therapeutics Inc.109.30+0.88%$8.99Bvs RGEN
HALOHalozyme Therapeutics Inc.109.84-0.86%$12.47Bvs RGEN

Related